Security key
604749101
Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)
CUSIP: 604749101
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 12,112
- Total 13F value
- $1,012,998
- Share change
- -8,980
- SEC-reported price per share
- $85.48
- Number of holders
- 7
- Value change
- -$767,588
- Number of buys
- 3
- Number of sells
- 4
- Shares outstanding
- 60,919,423
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
7
Top holders
10
MIRM full security history
Ownership snapshot
Full 13F holder table
Mirum Pharmaceuticals, Inc. SEC filings
Mirum Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 604749101
Recent filing periods:
Ownership snapshot
Top reported holders of MIRM - Mirum Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
21 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.7%
13D/G row: Janus Henderson Group Ltd.
Showing 1-6 of 15 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 9.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
9.7%
Frazier Life Sciences IX, L.P.
6.8%
FMR LLC
6.2%
BlackRock, Inc.
5.7%
EVENTIDE ASSET MANAGEMENT, LLC
4.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
|
9.7%
|
$759,743,787
5,909,184 shares
|
-$20,072,863 | 30 Jun 2026 |
| Frazier Life Sciences IX, L.P. |
13D/G
Patrick J. Heron
|
6.8%
|
$324,522,832
4,108,404 shares
|
+$29,477,804 | 23 Jan 2026 |
| FMR LLC |
13D/G
13F
Company
|
6.2%
|
$485,718,308
3,777,851 shares
|
$0 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.7%
from 13D/G
|
$513,944,677
4,390,063 shares
|
— | 30 Jun 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
13F
Company
|
4.1%
|
$165,372,042
2,093,582 shares
|
-$40,549,990 | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
3%
|
$109,619,710
1,495,290 shares
|
$0 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
12,112
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
324
Q3 2026 holders
7
Holder diff
-317
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend